logo tat2013 - klein 

Over 500 participants from 46 countries attended TAT 2013 in Paris, March 4-6, 2013, with 60 plenary lectures, presented by leading experts in clinical cancer research and oncology drug development:

  • NDDO Honorary Award Lecture 2013 by Jean-Pierre Armand: “Phase 1, a critical step for cancer drug development”
  • Keynote Lecture by Michael B. Atkins: “Targeting immune checkpoints in cancer therapy”
  • New immune checkpoints as targets: updates on four major drug development programs
  • Metabolic drug targets: updates on three major drug development programs
  • Drug targeting the RAS-RAF-MEK pathway: drugs for BRAF-, KRAS-mutant tumors, drug combinations involving MEK inhibition
  • Design and development of immunoconjugates and TLRLigand-long peptide conjugates
  • Phase 1 studies, completed or in progress: including new data never presented before
  • Whole-genome sequencing in patient selection for targeted therapies
  • Preclinical models in drug discovery and development
  • Collaborative phase 1 trials by small biotech and academia: recent examples and future perspectives

TO VIEW TAT 2013 PRESENTATIONS, CLICK "SLIDES" IN THE RIGHT-HAND MENU.


Don't miss future updates and keep following TAT Congress series via Twitter, LinkedIn and Facebook

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TAT 2014 abstracts
Download PDFs

TAT 2014 presentations
(PDF version)

TAT 2013 abstracts
Ann Oncol 2013 (Suppl)

TAT 2013 presentations
(PDF version)

TAT 2012 abstracts
Ann Oncol 2012 (Suppl)